Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549 Tieliang Wang1, Ying Liu2 and Chao Wu2*

Total Page:16

File Type:pdf, Size:1020Kb

Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549 Tieliang Wang1, Ying Liu2 and Chao Wu2* Wang et al. Nanoscale Research Letters (2017) 12:66 DOI 10.1186/s11671-017-1826-1 NANO EXPRESS Open Access Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549 Tieliang Wang1, Ying Liu2 and Chao Wu2* Abstract A nanodrug delivery system of paclitaxel-mesoporous silica nanoparticles with a core-shell structure (PAC-csMSN) was used to increase the dissolution of paclitaxel (PAC) and improve its treatment of lung cancer. PAC was loaded into the core-shell mesoporous silica nanoparticles (csMSN) by the adsorption equilibrium method and was in an amorphous state in terms of its mesoporous structure. In vitro and in vivo studies showed that csMSN increased the dissolution rate of PAC and improved its lung absorption. The area under concentration-time curve (AUC) value of PAC-csMSN used for pulmonary delivery in rabbits was 2.678-fold higher than that obtained with the PAC. After continuous administration for 3 days, a lung biopsy showed no signs of inflammation. Cell apoptosis results obtained by flow cytometry indicated that PAC-csMSN was more potent than pure PAC in promoting cell apoptosis. An absorption investigation of PAC-csMSN in A549 cells was carried out by transmission electron microscopy (TEM) and laser scanning confocal microscopy (LSCM). The obtained results indicated that the cellular uptake was time-dependent and csMSN was uptaken into the cytoplasm. All these results demonstrate that csMSN have the potential to achieve pulmonary inhalation administration of poorly water-soluble drugs for the treatment of lung cancer. Keywords: Mesoporous silica nanoparticles, Paclitaxel, A549 cells, Dissolution, Pulmonary delivery Background to improve the solubility of PAC has become an import- Most anticancer drugs are water-insoluble, and the poor ant challenge. Currently, some methods are available for solubility seriously restricts their absorption. Classical improving PAC solubility, such as the use of micelles, treatment for lung cancer involves oral or intravenous liposomes, and nanoparticles [7–9]. With the develop- administration of antifungal drug formulations [1–3]. ment of nanotechnology, the application of mesoporous However, these compounds have many side effects and materials for improving the solubility of poorly water- are not very effective [4]. For these common routes of soluble drugs is attracting wide attention. Zongzhe zhao administration, a stable and efficient lung drug concen- et al. have reported the development of mesoporous tration is not always guaranteed due to low solubility silica materials in improving the solubility of fenofibrate and/or poor tissue penetration, which may also lead to a and regulating its release rate [10]. Peng zhao et al. apply poor survival prognosis. Pulmonary delivery is an inter- mesoporous carbon materials to increase the dissolution esting choice because it delivers anticancer drugs rate of poorly water-soluble drugs [11]. Porous hydroxy- directly to the cancerous tissue while maintaining high apatite, porous alumina, and porous titanium dioxide lung drug concentrations and reducing systemic side materials have also been used to improve the water solu- effects [5, 6]. bility of insoluble drugs [12–14]. PAC, an effective anticancer drug, is poorly water- In our research, we have developed a csMSN-based soluble (solubility in water is 6 ng/ml). Therefore, how PAC nanodrug delivery system for improving the treat- ment of lung cancer. There are two reasons for choosing * Correspondence: [email protected] csMSN as carrier for improving PAC solubility. Firstly, 2Pharmacy School, Jinzhou Medical University, 40 Songpo Road, Linghe District, the spatial confinement effect of the mesoporous struc- Jinzhou, Liaoning Province 121000, China ture can reduce the drug particle size and increase the Full list of author information is available at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Wang et al. Nanoscale Research Letters (2017) 12:66 Page 2 of 8 specific surface area of the drug particles. According to in a vacuum. The drug content was determined by high- the Noyes-Whitney and Ostwald-Freundlich equations, performance liquid chromatography (HPLC) (L-2400, this would increase the dissolution rate of PAC. HITACHI, Japan). The drug loading (DD) of csMSN was Secondly, csMSN has a regular shape, low density, calculated by the formula: and good flowability which make them suitable as a carrier for pulmonary delivery. In the work, we DD ¼ the amount of drug in PAC−csMSN= wished to investigate whether csMSN could be used the amount of PAC−csMSN: as a pulmonary delivery carrier using a lung absorp- tion study at a cellular level. Characterization of csMSN and PAC-csMSN Methods The structure and morphology of csMSN was observed Materials by transmission electron microscopy (TEM; Tecnai PAC was provided by the Dalian Meilun Company with a G2F30) and scanning electron microscopy (SEM; JEOL purity >99%. Acetonitrile, anhydrous ethanol, butylpara- JSM-7001F). The adsorption analyzer (SA3100, Beckman ben, Tween 80, tetraethylorthosilicate (TEOS), aminopro- Coulter Inc., Brea, CA, USA) was used to detect the spe- pyltriethoxysilane (APTES), glutaraldehyde, hypromellose, cific surface area and pore size of csMSN. The phase hexadecyl trimethyl ammonium bromide (CTAB), ammo- transition process of PAC in all samples was performed nia, methyl tert-butyl ether, and dichloromethane were using differential scanning calorimetry (DSC; Shimadzu obtained from the Jin Zhou Xing Bei reagent company. DSC-60, Japan) at a heating rate of 10 °C/min from 25 Fluorescein isothiocyanate (FITC), Hoechst 33342, to 350 °C under a nitrogen flow of 150 ml/min. X-ray rhodamine phalloidin and 3-(4,5-Dimethylthiazol-2-yl)- diffraction analysis (XRD; Rigaku Geigerflex XRD, Co., 2,5-diphenyltetrazolium (MTT) were purchased from Japan,) was used to further investigate the physical state Beijing Dingguo Changsheng Biotechnology Co., Ltd. of PAC in csMSN. The step length was 0.02° and the Deionized water was used in all experiments. scanning rate was 4°/min from 3° (2θ) to 60°. FTIR spec- tra were recorded for analyzing the interaction PAC and Synthesis of csMSN csMSN using an FT-IR spectrometer (Bruker IFS 55, − csMSN was prepared according to the process reported Switzerland) over 400 to 4000 cm 1 using the KBr pellet by Wu et al. [15]. Firstly, ethanol, deionized water, and technique. ammonia (180:65:4.5, v/v/v) were mixed in a glass con- tainer under stirring. Then, TEOS (15 ml) was slowly In Vitro Drug Dissolution dripped into the solution. The reaction was carried out Dissolution testing was performed using a USP dissol- for 4 h and then solid silica nanoparticles (SSN) were ution apparatus type II (RC-8D, Tianjin Guoming obtained by centrifugation at 9500 rpm for 200 min. The Medical Equipment Co., Ltd.). The dissolution medium product was then dried at 40 °C. Secondly, ethanol, de- was pH 7.4 phosphate buffer with 1% Tween 80. For ionized water, CTAB, and the dried SSN (13:30:150:100, this, 10 mg PAC and PAC-csMSN powder containing an v/v/m/m) were mixed in a glass container and stirred for equivalent of 10 mg PAC were respectively put in 30 min under ultrasonication. Ammonia (0.45 ml) and 1000 ml dissolution medium at a temperature of 37 ± TEOS (0.3 ml) were then added to the system and 0.5 °C and the paddle speed was 100 rpm/min. Then, stirred at room temperature for 6 h. The precipitate ob- 5 ml samples of dissolution medium were withdrawn at tained by centrifugation was washed repeatedly with 5, 10, 15, 20, 30, 45, and 60 min and passed through a ethanol and water, and then dried at 40 °C. csMSN was 0.22 μm microporous membrane filter for HPLC ana- obtained by calcination at 550 °C. lysis. The detection wavelength was 227 nm, and the mobile phase was acetonitrile and water with a volume Drug-Loading Procedure ratio of 50:50 [17]. PAC, an anticancer drug, is used clinically to treat ovar- ian cancer, breast cancer, lung cancer, and colorectal In Vivo Pharmacokinetic Study cancer. It was chosen as a model drug and was loaded Animals and Dosing onto csMSN by the adsorption equilibrium method [16]. The animal experiment was approved by the Jinzhou The drug loading of csMSN was concentration- Medical University Laboratory Animal Ethics Committee. dependent. The same amount of csMSN was soaked in Twelve rabbits (2.5 ± 0.5 kg) were randomly assigned to different concentrations of PAC dichloromethane solution two groups for evaluating the pharmacokinetics of PAC- and then the suspension was stirred for 5 h. The super- csMSN powder and PAC powder after pulmonary natant was removed by centrifugation at 10,000 rpm and, administration. After fasting for 12 h, one group was given finally, the drug-loaded sample (PAC-csMSN) was dried a suspension of PAC-csMSN powder containing 2% Wang et al. Nanoscale Research Letters (2017) 12:66 Page 3 of 8 hypromellose (equivalent to 10 mg PAC) while the other 40, 80, 160, and 320 μg/ml of PAC concentration. MTT group was given an aqueous suspension of PAC powder solution (20 μl/well) was added and incubated for 4 h. (10 mg) containing 2% hypromellose by the trachea Next, DMSO (200 μl) was added and the cytotoxicity cannula-instillation method [18, 19]. All rabbits had free was determined by a Plate Reader (DNM-9606) at access to drinking water throughout the study. Blood sam- 492 nm (Tecan, Germany) [20]. ples (3.0 ml) were collected from the ear vein at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h and centrifuged at The Flow Cytometry Assays 5000 rpm for 10 min.
Recommended publications
  • 錦州銀行股份有限公司 Bank of Jinzhou Co., Ltd
    英文版-左_6_OP.pdf 1 21/11/15 上午3:42 C M Y CM MY CY CMY K IMPORTANT If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. 錦州銀行股份有限公司 Bank of Jinzhou Co., Ltd.* (a joint stock company incorporated in the People’s Republic of China with limited liability) GLOBAL OFFERING Number of Offer Shares under the : 1,320,000,000 H Shares (comprising Global Offering 1,200,000,000 H Shares to be offered by our Bank and 120,000,000 Sale Shares to be offered by the Selling Shareholders, subject to the Over-allotment Option) Number of International Offer Shares : 1,188,000,000 H Shares (subject to adjustment and the Over-allotment Option) Number of Hong Kong Offer Shares : 132,000,000 H Shares (subject to adjustment) Maximum Offer Price : HK$5.54 per H Share, plus brokerage fee of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) Nominal value : RMB1.00 per H Share Stock code : 416 Sole Sponsor Joint Global Coordinators Joint Bookrunners and Joint Lead Managers Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus.
    [Show full text]
  • Shengjing Bank Co., Ltd.* (A Joint Stock Company Incorporated in the People's Republic of China with Limited Liability) Stock Code: 02066 Annual Report Contents
    Shengjing Bank Co., Ltd.* (A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 02066 Annual Report Contents 1. Company Information 2 8. Directors, Supervisors, Senior 68 2. Financial Highlights 4 Management and Employees 3. Chairman’s Statement 7 9. Corporate Governance Report 86 4. Honours and Awards 8 10. Report of the Board of Directors 113 5. Management Discussion and 9 11. Report of the Board of Supervisors 121 Analysis 12. Social Responsibility Report 124 5.1 Environment and Prospects 9 13. Internal Control 126 5.2 Development Strategies 10 14. Independent Auditor’s Report 128 5.3 Business Review 11 15. Financial Statements 139 5.4 Financial Review 13 16. Notes to the Financial Statements 147 5.5 Business Overview 43 17. Unaudited Supplementary 301 5.6 Risk Management 50 Financial Information 6. Significant Events 58 18. Organisational Chart 305 7. Change in Share Capital and 60 19. The Statistical Statements of All 306 Shareholders Operating Institution of Shengjing Bank 20. Definition 319 * Shengjing Bank Co., Ltd. is not an authorised institution within the meaning of the Banking Ordinance (Chapter 155 of the Laws of Hong Kong), not subject to the supervision of the Hong Kong Monetary Authority, and not authorised to carry on banking and/or deposit-taking business in Hong Kong. COMPANY INFORMATION Legal Name in Chinese 盛京銀行股份有限公司 Abbreviation in Chinese 盛京銀行 Legal Name in English Shengjing Bank Co., Ltd. Abbreviation in English SHENGJING BANK Legal Representative ZHANG Qiyang Authorised Representatives ZHANG Qiyang and ZHOU Zhi Secretary to the Board of Directors ZHOU Zhi Joint Company Secretaries ZHOU Zhi and KWONG Yin Ping, Yvonne Registered and Business Address No.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Annual Report Is Published
    Contents 1. Company Information 2 8. Directors, Supervisors, Senior 73 2. Financial Highlights 4 Management and Employees 3. Chairman’s Statement 7 9. Corporate Governance Report 90 4. Honours and Awards 8 10. Report of the Board of Directors 117 5. Management Discussion and 9 11. Report of the Board of Supervisors 125 Analysis 12. Social Responsibility Report 128 5.1 Analysis of Overall 9 13. Internal Control 130 Operations 14. Independent Auditor’s Report 132 5.2 Financial Review 11 15. Financial Statements 142 5.3 Business Overview 44 16. Notes to the Financial Statements 150 5.4 Risk Management 52 17. Unaudited Supplementary 302 5.5 Environmental Outlook and 58 Financial Information Development Strategy 18. Organisational Chart 306 6. Significant Events 60 19. The Statistical Statements of All 307 7. Change in Share Capital and 64 Operating Institution of Shengjing Shareholders Bank 20. Definition 323 * Shengjing Bank Co., Ltd. is not an authorised institution within the meaning of the Banking Ordinance (Chapter 155 of the Laws of Hong Kong), not subject to the supervision of the Hong Kong Monetary Authority, and not authorised to carry on banking and/or deposit-taking business in Hong Kong. Chapter 1 Company Information COMPANY INFORMATION Legal Name in Chinese 盛京銀行股份有限公司 Abbreviation in Chinese 盛京銀行 Legal Name in English Shengjing Bank Co., Ltd. Abbreviation in English SHENGJING BANK Legal Representative QIU Huofa Authorised Representatives QIU Huofa and ZHOU Zhi Secretary to the Board of Directors ZHOU Zhi Joint Company Secretaries
    [Show full text]
  • Directors, Supervisors and Parties Involved in the [Redacted]
    THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. DIRECTORS, SUPERVISORS AND PARTIES INVOLVED IN THE [REDACTED] DIRECTORS 3rd Sch(6) A1A41(1) Name Residential Address Nationality Executive Directors Mr. ZHANG Wei (張偉先生) Flat 15, Block A Chinese (Chairman) Wantong Apartment Shiying South Street Guta District Jinzhou City Liaoning Province PRC Ms. CHEN Man (陳漫女士) Unit 3-2-1601 Chinese Yanlord Riverside Plaza No. 131 Dongma Road Nankai District Tianjin City PRC Ms. ZHAO Jie (趙傑女士) Flat 10, Block E Chinese Wantong Apartment Guta District Jinzhou City Liaoning Province PRC Mr. WANG Jing (王晶先生) 7-III-13, Juhua Li Chinese Linghe District Jinzhou City Liaoning Province PRC Ms. WANG Xiaoyu Flat 65, Block I Chinese (王曉宇女士) Wantong Apartment Shiying South Street Guta District Jinzhou City Liaoning Province PRC —71— THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. DIRECTORS, SUPERVISORS AND PARTIES INVOLVED IN THE [REDACTED] Name Residential Address Nationality Non-executive Directors Mr. LI Dongjun (李東軍先生) No. 6, Level 15, Unit 1 Chinese No. 4 Xiuzhu Street Zhong Shan District Dalian City PRC Mr. ZHANG Caiguang 3002 Unit 2 Chinese (張財廣先生) Building No. 14 Court 8 Lize West Street Chaoyang District Beijing City PRC Mr. WU Zhengkui 703 Chinese (吳正奎先生) No. 34 Lane 2250 Dongjing Road Shanghai City PRC Ms. GU Jie (顧潔女士) 5-4-902 Dahezhuangyuan Chinese No.
    [Show full text]
  • Demystifying Chinese Investment in Australia
    Bank of Jinzhou Co., Ltd. 2016 Environmental, Social and Governance Report Stock Code: 0416 Contents About this Report 1 Message from the Chairman 2 Message from the President 3 I. About Us 5 II. Social Responsibility Management 9 1.1 Company Profile 5 2.1 Social Responsibility Concepts 9 1.2 Honours and Awards 6 2.2 Social Responsibility Management System 10 1.3 Key Performance Indicators 7 2.3 Stakeholder Participation 11 2.4 Analysis of Material Issues 12 III. Supporting Real Economy 15 IV. Shareholder Returns 21 3.1 Revitalising the Old Industrial Base 4.1. Improving Economic Benefits 21 of Northeast China 15 4.2 Improving Corporate Governance 22 3.2 Supporting the Growth of "Three 4.3 Enhancing Internal Control 24 Basis & Three Smalls" 16 4.4 Enhancing Risk Management 27 3.3 Improving the Capabilities of Providing Agriculture-related Financial Services 18 3.4 Supporting the Development of Emerging Industries 19 V. Serving Customers 29 VI. Caring for the Staff 37 5.1 Innovating Financial Products 29 6.1 Protecting the Rights and Interests of the Staff 37 5.2 Improving Service Quality 30 6.2 Supporting Career Development 39 5.3 Expanding Service Channels 32 6.3 Enhancing Humanism 40 5.4 Protecting Customers' Rights and Interests 33 6.4 Enriching the Leisure Life of the Staff 41 VII. Protecting Environment 45 VIII. Reciprocating the Society 51 7.1 Supporting Green Credits 45 8.1 Promoting Targeted Poverty Alleviation 51 7.2 Developing Electronic Banking 46 8.2 Helping Disadvantaged Groups 53 7.3 Advocating Low-carbon Operation 47 8.3 Carrying out Voluntary Services 54 7.4 Organising Environmental Protection Campaigns 49 Prospect for 2017 56 Independent Limited Assurance Report 57 ESG Indicator Index 60 Feedback from Readers 64 2016 Bank of Jinzhou Environmental, Social and Governance Report Environmental, Social and Governance Report | 2016 1 About this Report This report describes the performance of Bank of Jinzhou Co., Ltd.
    [Show full text]
  • The Interaction Between Serum Uric
    Zhang et al. BMC Cardiovascular Disorders (2020) 20:174 https://doi.org/10.1186/s12872-020-01468-3 RESEARCH ARTICLE Open Access The interaction between serum uric acid and triglycerides level on blood pressure in middle-aged and elderly individuals in China: result from a large national cohort study Lin Zhang1, Jin-long Li2, Lei-lei Guo1, Hong Li1, Dan Li3 and Guang Xu4* Abstract Background: The purpose of the research was to explore the extent of interaction between triglycerides (TG) and serum uric acid (SUA) level with blood pressure (BP) in middle-aged and elderly individuals in China. Methods: Data were selected from the China Health and Retirement Longitudinal Study (CHARLS), a cross-sectional study. 3345(46.99%) men with average ages of 60.24 ± 9.24 years and 3774 (53.01%) women with average ages of 59.91 ± 9.95 years were included in the study. Differences between gender, or between categories of blood pressure levels were evaluated by t-test or chi-square test. The adjusted associations between various characteristics and BP status were first compared using linear regression models, as appropriate. Then, A general linear model adjusted for confounding factors (socio-demographic characteristics [age, educational levels, marital status, place of residence], health behaviors [cigarette smoking, alcohol drinking, eating habits, social and leisure activities, accidental injury, physical activities], medical history [history of cardiovascular diseases, hepatitis history, antidiabetic drugs, history of antilipidemic medication, anti-hypertensive therapy], metabolic measures [C-reactive protein (CRP), hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), estimated glomerular filtration rate (eGFR), body mass index (BMI)]) was used to examine the synergistic effect of SUA and TG level on BP in middle-aged and elderly individuals in China.
    [Show full text]
  • Area Comprehensive Score 1990 2000 2010 Heping District 0.307
    Comprehensive score of aging level in 1990, 2000 and 2010 Comprehensive score Area 1990 2000 2010 Heping District 0.307 0.572 0.792 Shenhe District 0.319 0.554 0.774 Dadong District 0.275 0.558 0.803 Huanggu District 0.262 0.542 0.777 Tiexi District (Shenyang) 0.252 0.611 0.800 Sujiatun District 0.202 0.409 0.699 Dongling District 0.202 0.370 0.512 Shenbei New District 0.196 0.388 0.534 Yuhong District 0.197 0.364 0.593 Liaozhong County 0.187 0.351 0.627 Kangping County 0.165 0.318 0.604 Faku County 0.195 0.354 0.653 Xinmin City 0.177 0.351 0.627 Zhongshan District 0.336 0.592 0.888 Xigang District 0.327 0.605 0.860 Shahekou District 0.284 0.534 0.770 Ganjingzi District 0.242 0.381 0.557 Lushunkou District 0.302 0.427 0.668 Jinzhou District 0.267 0.360 0.531 Changhai County 0.215 0.314 0.638 Wafangdian City 0.218 0.431 0.799 Pulandian City 0.243 0.440 0.812 Zhuanghe City 0.224 0.460 0.778 Tiedong District 0.230 0.541 0.831 Tiexi District (Anshan) 0.234 0.514 0.896 Lishan District 0.198 0.540 0.950 Qianshan District 0.215 0.399 0.721 Tai'an County 0.187 0.355 0.613 Xiuyan Manchu Autonomous County 0.171 0.349 0.620 Haicheng City 0.191 0.321 0.573 Xinfu District 0.245 0.517 0.853 Dongzhou District 0.230 0.551 1.000 Wanghua District 0.206 0.464 0.814 Shuncheng District 0.195 0.479 0.819 Fushun County 0.256 0.401 0.701 Xinbin Manchu Autonomous County 0.110 0.298 0.615 Qingyuan Manchu Autonomous County 0.124 0.318 0.618 Pingshan District 0.208 0.475 0.778 Xihu District 0.217 0.497 0.829 Mingshan District 0.186 0.440 0.743 Nanfen District 0.196
    [Show full text]
  • ADB's Trade Finance Program Confirming Banks List
    Trade Finance Program Confirming Banks List As of 13 February 2017 AFGHANISTAN Bank Alfalah Limited (Afghanistan Branch) 410 Chahri-e-Sadarat Shar-e-Nou, Kabul, Afghanistan National Bank of Pakistan (Jalalabad Branch) Bank Street Near Haji Qadeer House Nahya Awal, Jalalabad, Afghanistan National Bank of Pakistan (Kabul Branch) House No. 2, Street No. 10 Wazir Akbar Khan, Kabul, Afghanistan ALGERIA HSBC Bank Middle East Limited, Algeria 10 Eme Etage El-Mohammadia 16212, Alger, Algeria ANGOLA Banco Millennium Angola SA Rua Rainha Ginga 83, Luanda, Angola ARGENTINA Banco Patagonia S.A. Av. De Mayo 701 24th floor C1084AAC, Buenos Aires, Argentina Banco Rio de la Plata S.A. Bartolome Mitre 480-8th Floor C1306AAH, Buenos Aires, Argentina AUSTRALIA Australia and New Zealand Banking Group Limited Level 20, 100 Queen Street, Melbourne, VIC 3000, Australia Australia and New Zealand Banking Group Limited (Adelaide Branch) Level 20, 11 Waymouth Street, Adelaide, Australia Australia and New Zealand Banking Group Limited (Adelaide Branch - Trade and Supply Chain) Level 20, 11 Waymouth Street, Adelaide, Australia Australia and New Zealand Banking Group Limited (Brisbane Branch) Level 18, 111 Eagle Street, Brisbane QLD 4000, Australia Australia and New Zealand Banking Group Limited (Brisbane Branch - Trade and Supply Chain) Level 18, 111 Eagle Street, Brisbane QLD 4000, Australia Australia and New Zealand Banking Group Limited (Perth Branch) Level 6, 77 St Georges Terrace, Perth, Australia Australia and New Zealand Banking Group Limited (Perth Branch
    [Show full text]
  • Fujitsu Client Computing Devices Authorized Service Center
    Fujitsu Client Computing Devices Authorized Service Center Country: China Issue: 22nd Jul, 2018 Products: CELSIUS, ESPRIMO, LIFEBOOK, STYLISTIC, DISPLAY and Accessories Customer Service / Technical Support Hotline (Local Toll Free): 4000887716 Location Service Provider Address Telephone Business Hours Language 9:00am - 6:00pm English, Anshan Anshang Mingpin Co.,Ltd No.92, 13F, Silong Plaza, Tiedong Area, Anshang, Liaoning (86) 0412 2988356 (Mon - Sat) Mandarin Beijing Digital China Instant Room 203, Zhong Jia Plaza,East Da Zhong Si, Haidian, (86) 010-86470361 9:00am - 6:00pm English, Beijing Technology Service Co.,Ltd Beijing (86) 010-86470362 (Mon - Sat) Mandarin Beijing Digital China Instant Changsha furong district 21 families and better computer city 9:00am - 6:00pm English, Changsha (86) 0731-84152927 Technology Service Co.,Ltd Station Road building B 26 floor, room 2604, 2605 (Mon - Sat) Mandarin Changzhou Juyi Information Room 1011,Building 10, 15-1,Jiuzhou Digital Center, No.99, 9:00am - 6:00pm English, Changzhou (86) 519 85785712 Technology Co.,Ltd West Laodong Road, Tianning Area, Changzhou (Mon - Sat) Mandarin Beijing Digital China Instant A5, 27F, Building A, Digital Plaza, No.1, Siduan, South 9:00am - 6:00pm English, Chengdu Technology Service Co., LTD (86) 028 85482706 People Road, Wuhou Area, Chengdu (Mon - Sat) Mandarin (Chengdu) Chongqing Pinliang Technology The 9 floor shop No. 9-6-1, Taixing computer city bridge in 9:00am - 6:00pm English, Chongqing (86) 023 68794974 Co.,Ltd Chongqing City (Mon - Sat) Mandarin Chaoyang District City, No. 1313 road workers and peasants 9:00am - 6:00pm English, Chuangchun Changchun Ruilian Co.,Ltd (86) 0431 87065663 Changchun Bainaohui Hongqi Street, room 2022 (Mon - Sat) Mandarin Xinglin street in Zhongshan District of Dalian City, No.
    [Show full text]
  • 2020 ANNUAL REPORT * Bank of Jinzhou Co., Ltd
    2020 ANNUAL REPORT * Bank of Jinzhou Co., Ltd. is not an authorized institution within the meaning of the Banking Ordinance (Chapter 155 of the Laws of Hong Kong), not subject to the supervision of the Hong Kong Monetary Authority, and not authorized to carry on banking and/or deposit-taking business in Hong Kong. Contents 2 Definitions 4 Chapter 1 Company Profile 7 Chapter 2 Financial Highlights 10 Chapter 3 Chairman’s Statement 12 Chapter 4 President’s Statement 14 Chapter 5 Management Discussion and Analysis 76 Chapter 6 Changes in Ordinary Shares and Particulars of Shareholders 85 Chapter 7 Particulars of Offshore Preference Shares 88 Chapter 8 Directors, Supervisors, Senior Management, Employees and Organizations 105 Chapter 9 Corporate Governance Report 130 Chapter 10 Directors’ Report 142 Chapter 11 Supervisors’ Report 144 Chapter 12 Social Responsibility Report 146 Chapter 13 Internal Control and Internal Audit 149 Chapter 14 Important Events 155 Chapter 15 Independent Auditor’s Report and Financial Statements 305 Chapter 16 Unaudited Supplementary Financial Information Bank of Jinzhou Co., Ltd. 2020 Annual Report 1 Definitions In this annual report, unless the context otherwise requires, the following terms shall have the meanings set out below: “Articles of Association” the articles of association of the Bank, as amended from time to time “Bank”, “Bank of Jinzhou” or “Group” Bank of Jinzhou Co., Ltd. (錦州銀行股份有限公司), a joint stock company incorporated in the PRC on 22 January 1997 with limited liability in accordance with PRC laws
    [Show full text]
  • Annual Development Report on China's Trademark Strategy 2013
    Annual Development Report on China's Trademark Strategy 2013 TRADEMARK OFFICE/TRADEMARK REVIEW AND ADJUDICATION BOARD OF STATE ADMINISTRATION FOR INDUSTRY AND COMMERCE PEOPLE’S REPUBLIC OF CHINA China Industry & Commerce Press Preface Preface 2013 was a crucial year for comprehensively implementing the conclusions of the 18th CPC National Congress and the second & third plenary session of the 18th CPC Central Committee. Facing the new situation and task of thoroughly reforming and duty transformation, as well as the opportunities and challenges brought by the revised Trademark Law, Trademark staff in AICs at all levels followed the arrangement of SAIC and got new achievements by carrying out trademark strategy and taking innovation on trademark practice, theory and mechanism. ——Trademark examination and review achieved great progress. In 2013, trademark applications increased to 1.8815 million, with a year-on-year growth of 14.15%, reaching a new record in the history and keeping the highest a mount of the world for consecutive 12 years. Under the pressure of trademark examination, Trademark Office and TRAB of SAIC faced the difficuties positively, and made great efforts on soloving problems. Trademark Office and TRAB of SAIC optimized the examination procedure, properly allocated examiners, implemented the mechanism of performance incentive, and carried out the “double-points” management. As a result, the Office examined 1.4246 million trademark applications, 16.09% more than last year. The examination period was maintained within 10 months, and opposition period was shortened to 12 months, which laid a firm foundation for performing the statutory time limit. —— Implementing trademark strategy with a shift to effective use and protection of trademark by law.
    [Show full text]